186 - Next-Generation COVID-19 Vaccines

Friday, October 13, 2023

3:15 PM – 4:30 PM US ET

Location: 156 ABC

All relevant financial disclosures have been mitigated.

Moderator(s)

Lisa Jackson, MD, MPH (she/her/hers)

Senior Investigator
Kaiser Permanente Washington Health Research Institute
Seattle, WA, United States
Catherine Mary Healy, MD, FIDSA (she/her/hers)

Associate Professor of Pediatrics
Baylor College of Medicine
Houston, TX, United States

Faculty(s)

Brett Case, PhD

Instructor in Medicine
Washington University School of Medicine
Saint Louis, MO, United States
Kevin Saunders, PhD (he/him/his)

Associate Director
Duke Human Vaccine Institute
Durham, North Carolina, United States

Slides
Michael Osterholm, PhD, MPH (he/him/his)

Director, CIDRAP
Center for Infectious Disease Research and Policy, University of Minnesota
Minneapolis, MN, United States

Slides

Disclosure(s):

Lisa Jackson, MD, MPH: Pfizer, Inc.: Grant/Research Support (Ongoing)

Catherine Mary Healy, MD, FIDSA: Dexcom Inc: Stocks/Bonds (Ongoing); Emmes Corporation: SMC member (Terminated); Intuitive Surgical Inc: Stocks/Bonds (Ongoing); Quidel Corporation: Stocks/Bonds (Ongoing); Vapotherm: Stocks/Bonds (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the considerations involved in evaluating possible next generation vaccines;
identify features of a possible pan-coronavirus vaccine;
explain differences in the development and evaluation of parenteral and mucosal vaccines

Presentations:

3:15 PM – 3:40 PM US ET

Development of a Pan-Sarbecovirus Mucosal Vaccine
Speaker: Brett Case, PhD – Washington University School of Medicine
3:40 PM – 4:05 PM US ET

Developing a Neutralizing Antibody Vaccine for Pandemic and Pre-Emergent Coronaviruses
Speaker: Kevin O. Saunders, PhD (he/him/his) – Duke Human Vaccine Institute
4:05 PM – 4:30 PM US ET

A Coronavirus Vaccine Roadmap: Advancing a Global R&D Agenda for Broadly Protective Coronavirus Vaccines
Speaker: Michael Osterholm, PhD, MPH (he/him/his) – Center for Infectious Disease Research and Policy, University of Minnesota